Back to search results

Study of Eloralintide for Persistent Obesity

This study is testing a drug called Eloralintide (LY3841136) to see if it can help people with persistent obesity or who are overweight. You could be eligible if you are already taking a weekly incretin therapy (a type of medication for weight management or diabetes) and still have obesity or are overweight. This includes if you have a BMI (Body Mass Index) of 30 or higher, or a BMI of 27 or higher with related health issues like high blood pressure or sleep apnea. The main goal is to see how much Eloralintide changes body weight compared to a placebo (an inactive substance) over 64 weeks, and to check its safety. The study plans to enroll about 900 participants.

Study design
This is an interventional study comparing Eloralintide to a placebo, administered by injection under the skin. It plans to enroll about 900 participants.
What's involved
Participation in the study will last about 80 weeks. Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your body weight will be measured at the beginning of the study and again at Week 64.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07392190

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Recruiting
PHASE3Ages 18+InterventionalTreatment
Eli Lilly and Company
~900 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:EloralintidePlacebo

At a glance

Recruiting sites
121 of 187 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent Change from Baseline in Body Weight
Measured over Baseline, Week 64

Conditions

Overweight
Obesity

Explore related trials

ObesityOverweight

Where it's being run

187 sites across 35 states
China22
Israel17
India12
Japan11
Texas10
Australia10
Romania10
Spain10

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Are on stable incretin therapy at screening
With persistent obesity or overweight defined as:
≥30 kg/m2 OR
≥27 kg/m2 with at least one existing obesity related complication at screening:
hypertension
dyslipidemia
obstructive sleep apnea
cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or
type 2 diabetes
Have a stable body weight (\<5% body weight change) at screening

Exclusion

Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
Have type 1 diabetes
Have taken any of the following antihyperglycemic medications within 90 days before screening:
dipeptidyl peptidase-4 (DPP-4) inhibitors
amylin analogs
insulin
Have had within 90 days prior to screening:
heart attack
stroke
coronary artery revascularization
unstable angina, or
hospitalization due to congestive heart failure
Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

What this trial measures

  • Percent Change from Baseline in Body WeightBaseline, Week 64